Inclusion Criteria:

          1. Volunteer and sign informed consent forms

          2. Male or female Chinese patients, age ≥ 18 years old

          3. In patients with primary or secondary aml diagnosed according to (who) classification
             of the World Health Organization, patients with FLT3 mutation were detected by
             leukemia cell gene, and refractory aml; after at least one cycle of induction
             treatment of: a) met any of the following conditions. B) recurrent aml; after at least
             one cycle of induction therapy

          4. Ecog score 0-3

          5. Expected survival time greater than 3 months

          6. The study drug was at least 2 weeks apart from prior cytotoxic chemotherapy (except
             for hydroxyl groups), or at least 5 half-lives or 4 weeks with prior non-cytotoxic
             chemotherapy agents, short-term

          7. Upper limit of normal value of serum creatinine ≤ 1.5 times

          8. The upper limit of the normal value of total bilirubin ≤ 1.5 times, except for
             gilbert's syndrome and leukemia involving organs.

          9. Upper limit of serum AST,ALT ≤ 3.0 times normal value, except where leukemia involves
             organs

         10. The subjects of childbearing age agreed to take effective contraceptives during the
             treatment and 6 months after the completion of the treatment.

        Exclusion Criteria:

          1. Diagnosed acute promyelocytic leukemia

          2. Recent symptomatic central neurosystemic leukemia

          3. There are grade 2 or more non-hematological toxicity caused by previous chemotherapy

          4. Bone marrow transplants within 100 days of the study

          5. Uncontrollable active infections (acute or chronic fungi, bacteria, viruses, or other
             infections)

          6. Major surgical treatment of major organs was performed in the first 4 weeks of the
             study

          7. Radiotherapy was performed within 4 weeks before entering the study

          8. Cardiac ejection fraction below 50% or below the lower limit of normal value; patients
             with prolonged history of qtc (male > 450 Ms, female > 470ms); severe history of heart

          9. Hiv positive

         10. Active hepatitis B virus infection (hepatitis B virus surface antigen positive and
             hepatitis B dna quantity ≥ 1 × 10^3copies/ml), hepatitis C virus infection or other
             liver diseases

         11. Pregnant or lactating women

         12. There are serious diseases or complications, or diseases that the researchers
             determine may endanger the safety of the patient or interfere with the study

         13. Patients who are not considered to be able to enter the study

         14. Treatment is currently under way in another clinical trial or in another clinical
             trial within four weeks of the commencement of SKLB1028 treatment

         15. Patients who have previously received sklb1028 or other FLT3 inhibitors
             (midostaurin,gilteritinib, quizartinib)